Predictive Biomarkers of Response to Checkpoint Inhibitors in Triple Negative Breast Cancer: a Multiomics Platform

Whole genome sequencing (WGS) will be performed in tumor tissue from baseline and from residual disease after neoadjuvant chemotherapy (NACT), if present.

RNA-Sequencing will be performed in tumor tissue from baseline and from residual disease after NACT (if present).

Microbiome analysis will be performed in stools and saliva before, during NACT and at the end of adjuvant systemic therapy if adjuvant systemic therapy is clinically indicated.

ctDNA analysis will be performed in plasma before and during NACT.

TCR-β repertoire sequencing will be performed in plasma before and during NACT.

PBMCs phenotyping will be performed in plasma before and during NACT.

Pembrolizumab will be given in combination with standard NACT.

Standard NACT will be given.